The current state of targeted agents in rectal cancer

International Journal of Surgical Oncology

Volumn 2012, Issue , 2012, Pages

  Kim, Dae Dong ^a   Eng, Cathy ^b  

^a Catholic University of Daegu   (South Korea)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866177931     PISSN: 20901402     EISSN: 20901410     Source Type: Journal    
DOI: 10.1155/2012/406830     Document Type: Review

References (138)

1. Krook J. E., Moertel C. G., Gunderson L. L., Wieand H. S., Collins R. T., Beart R. W., Kubista T. P., Poon M. A., Meyers W. C., Mailliard J. A., Twito D. I., Morton R. F., Veeder M. H., Witzig T. E., Cha S., Vidyarthi C., Effective surgical adjuvant therapy for high-risk rectal carcinoma. The New England Journal of Medicine 1991 324 11 709 715 2-s2.0-0026071185
2. Rich T., Gunderson L. L., Lew R., Galdibini J. J., Cohen A. M., Donaldson G., Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983 52 7 1317 1329 (Pubitemid 13006473)
3. Gastrointestinal Tumor Study Group, Prolongation of the disease free interval in surgically treated rectal carcinoma. The New England Journal of Medicine 1985 312 23 1465 1472
4. Wolmark N., Wieand H. S., Hyams D. M., Colangelo L., Dimitrov N. V., Romond E. H., Wexler M., Prager D., Cruz A. B., Gordon P. H., Petrelli N. J., Deutsch M., Mamounas E., Wickerham D. L., Fisher E. R., Rockette H., Fisher B., Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: national surgical adjuvant breast and bowel project protocol R-02. Journal of the National Cancer Institute 2000 92 5 388 396 2-s2.0-0034162884 (Pubitemid 30154820)
5. Enker W. E., Total mesorectal excisionthe new golden standard of surgery for rectal cancer. Annals of Medicine 1997 29 2 127 133 2-s2.0-0030914380 (Pubitemid 27226321)
6. Sauer R., Becker H., Hohenberger W., Rödel C., Wittekind C., Fietkau R., Martus P., Tschmelitsch J., Hager E., Hess C. F., Karstens J. H., Liersch T., Schmidberger H., Raab R., Preoperative versus postoperative chemoradiotherapy for rectal cancer. The New England Journal of Medicine 2004 351 17 1731 1740 2-s2.0-6044226542 10.1056/NEJMoa040694 (Pubitemid 39383208)
7. Folkesson J., Birgisson H., Pahlman L., Cedermark B., Glimelius B., Gunnarsson U., Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. Journal of Clinical Oncology 2005 23 24 5644 5650 2-s2.0-24944534960 10.1200/JCO.2005.08.144
8. Kapiteijn E., Marijnen C. A. M., Nagtegaal I. D., Putter H., Steup W. H., Wiggers T., Rutten H. J. T., Pahlman L., Glimelius B., van Krieken J. H. J. M., Leer J. W. H., van de Velde C. J. H., Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. The New England Journal of Medicine 2001 345 9 638 646 2-s2.0-0035975394 10.1056/NEJMoa010580
9. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine 2004 350 23 2335 2342 2-s2.0-2542561964 10.1056/NEJMoa032691 (Pubitemid 38702844)
10. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine 2004 351 4 337 345 2-s2.0-3242720345 10.1056/NEJMoa033025 (Pubitemid 38944402)
11. Jonker D. J., O'Callaghan C. J., Karapetis C. S., Zalcberg J. R., Tu D., Au H. J., Berry S. R., Krahn M., Price T., Simes R. J., Tebbutt N. C., van Hazel G., Wierzbicki R., Langer C., Moore M. J., Cetuximab for the treatment of colorectal cancer. The New England Journal of Medicine 2007 357 20 2040 2048 2-s2.0-36148941301 10.1056/NEJMoa071834 (Pubitemid 350106711)
12. van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., Canon J. L., van Laethem J. L., Maurel J., Richardson G., Wolf M., Amado R. G., Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 2007 25 13 1658 1664 2-s2.0-34147103678 10.1200/JCO.2006.08.1620 (Pubitemid 46797944)
13. Definition of targeted therapyNCI dictionary of cancer terms. 2009
14. Scappaticci F. A., Fehrenbacher L., Cartwright T., Hainsworth J. D., Heim W., Berlin J., Kabbinavar F., Novotny W., Sarkar S., Hurwitz H., Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. Journal of Surgical Oncology 2005 91 3 173 180 2-s2.0-24344442899 10.1002/jso.20301 (Pubitemid 41254420)
15. Czito B. G., Bendell J. C., Willett C. G., Morse M. A., Blobe G. C., Tyler D. S., Thomas J., Ludwig K. A., Mantyh C. R., Ashton J., Yu D., Hurwitz H. I., Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. International Journal of Radiation Oncology Biology Physics 2007 68 2 472 478 2-s2.0-34247848005 10.1016/j.ijrobp.2007.02. 001 (Pubitemid 46694189)
16. Saltz L. B., Diaz-Rubio E., Scheithauer W., Clarke S., Figer A., Wong R., Koski S., Lichinitser M., Yang T. S., Rivera F., Couture F., Sirzén F., Cassidy J., Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology 2008 26 12 2013 2019 2-s2.0-42949149159 10.1200/JCO.2007.14.9930
17. Giantonio B. J., Catalano P. J., Meropol N. J., O'Dwyer P. J., Mitchell E. P., Alberts S. R., Schwartz M. A., Benson A. B., Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. Journal of Clinical Oncology 2007 25 12 1539 1544 2-s2.0-34248173883 10.1200/JCO.2006.09.6305 (Pubitemid 46733080)
18. Cascinus S., Garziano F., Catalano V., Vascular endothelial growth factor (VEGF), p53, and BAX expression in node positive rectal cancer. American Society of Clinical Oncology Proceedings 2001 20, article 595
19. Kozin S. V., Boucher Y., Hicklin D. J., Bohlen P., Jain R. K., Suit H. D., Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Research 2001 61 1 39 44 2-s2.0-0035132923 (Pubitemid 32095696)
20. Jain R. K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005 307 5706 58 62 2-s2.0-11844254414 10.1126/science.1104819 (Pubitemid 40093472)
21. Lee C. G., Heijn M., di Tomaso E., Griffon-Etienne G., Ancukiewicz M., Koike C., Park K. R., Ferrara N., Jain R. K., Suit H. D., Boucher Y., Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Research 2000 60 19 5565 5570 2-s2.0-0034306974
22. Tong R. T., Boucher Y., Kozin S. V., Winkler F., Hicklin D. J., Jain R. K., Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Research 2004 64 11 3731 3736 2-s2.0-2542628099 10.1158/0008-5472.CAN-04-0074 (Pubitemid 38697278)
23. van Cutsem E., Kohne C. H., Hitre E., Zaluski J., Chien C. R. C., Makhson A., D'Haens G., Pintér T., Lim R., Bodoky G., Roh J. K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine 2009 360 14 1408 1417 2-s2.0-63849088630 10.1056/NEJMoa0805019
24. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J. T., Aparicio J., de Braud F., Donea S., Ludwig H., Schuch G., Stroh C., Loos A. H., Zubel A., Koralewski P., Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology 2009 27 5 663 671 2-s2.0-59949091448 10.1200/JCO.2008.20. 8397
25. Spigel D. R., Bendell J. C., McCleod M., Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clinical Colorectal Cancer 2012 11 1 45 52 10.1016/j.clcc.2011.04.002
26. Maughan T. S., Adams R., Smith C. G., Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy in first-line advanced colorectal cancer: mature results of the MRC COIN trial. Journal of Clinical Oncology 2009 28, article 3502
27. Hoffheinz R.-D., Horisberger K., Woernle C., Wenz F., Kraus-Tiefenbacher U., Kähler G., Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan and radiotherapy as neoadjuvant therapy for rectal cancer. International Journal of Radiation Oncology Biology Physics 2006 66 1384 1390
28. Karapetis C. S., Khambata-Ford S., Jonker D. J., O'Callaghan C. J., Tu D., Tebbutt N. C., Simes R. J., Chalchal H., Shapiro J. D., Robitaille S., Price T. J., Shepherd L., Au H. J., Langer C., Moore M. J., Zalcberg J. R., K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine 2008 359 17 1757 1765 2-s2.0-54949085398 10.1056/NEJMoa0804385
29. Willett C. G., Duda D. G., di Tomaso E., Boucher Y., Ancukiewicz M., Sahani D. V., Lahdenranta J., Chung D. C., Fischman A. J., Lauwers G. Y., Shellito P., Czito B. G., Wong T. Z., Paulson E., Poleski M., Vujaskovic Z., Bentley R., Chen H. X., Clark J. W., Jain R. K., Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. Journal of Clinical Oncology 2009 27 18 3020 3026 2-s2.0-67649921334 10.1200/JCO.2008.21.1771
30. Duda D. G., Willett C. G., Ancukiewicz M., di Tomaso E., Shah M., Czito B. G., Bentley R., Poleski M., Lauwers G. Y., Carroll M., Tyler D., Mantyh C., Shellito P., Clark J. W., Jain R. K., Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 2010 15 6 577 583 2-s2.0-77954991606 10.1634/theoncologist.2010-0029
31. Carpenter G., The biochemistry and physiology of the receptor-kinase for epidermal growth factor. Molecular and Cellular Endocrinology 1983 31 1 1 19 2-s2.0-0020577827 (Pubitemid 13066937)
32. Saeki T., Salomon D. S., Johnson G. R., Gullick W. J., Mandai K., Yamagami K., Moriwaki S., Tanada M., Takashima S., Tahara E., Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Japanese Journal of Clinical Oncology 1995 25 6 240 249 2-s2.0-0029441596
33. Nicholson R. I., Gee J. M. W., Harper M. E., EGFR and cancer prognosis. European Journal of Cancer 2001 37 supplement 4 S9 S15 2-s2.0-0034778447 (Pubitemid 32938124)
34. Khorana A., Ryan C., Eberly S., EGFR expression and survival in stage II, III and IV colon cancer. American Society of Clinical Oncology Proceedings 2003 22, article 317
35. Amado R. G., Wolf M., Peeters M., van Cutsem E., Siena S., Freeman D. J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S. D., Chang D. D., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008 26 10 1626 1634 2-s2.0-42649145667 10.1200/JCO.2007.14.7116
36. di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., de Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A., Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Journal of Clinical Oncology 2008 26 35 5705 5712 2-s2.0-57449095367 10.1200/JCO.2008.18.0786
37. Maughan T., Adams R. A., Smith C. G., Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). European Journal of Cancer 2009 7 3, supplement, article 4
38. Debucquoy A., Haustermans K., Daemen A., Aydin S., Libbrecht L., Gevaert O., de Moor B., Tejpar S., McBride W. H., Penninckx F., Scalliet P., Stroh C., Vlassak S., Sempoux C., Machiels J. P., Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. Journal of Clinical Oncology 2009 27 17 2751 2757 2-s2.0-67649962407 10.1200/JCO.2008.18.5033
39. Kabbinavar F., Hurwitz H. I., Fehrenbacher L., Meropol N. J., Novotny W. F., Lieberman G., Griffing S., Bergsland E., Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2003 21 1 60 65 2-s2.0-0037208589
40. Fuchs C. S., Marshall J., Mitchell E., Wierzbicki R., Ganju V., Jeffery M., Schulz J., Richards D., Soufi-Mahjoubi R., Wang B., Barrueco J., Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. Journal of Clinical Oncology 2007 25 30 4779 4786 2-s2.0-36048960109 10.1200/JCO.2007.11.3357 (Pubitemid 350086481)
41. Fuchs C. S., Marshall J., Barrueco J., Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. Journal of Clinical Oncology 2008 26 4 689 690 2-s2.0-39149108869 10.1200/JCO.2007.15.5390 (Pubitemid 351264373)
42. Grothey A., Sugrue M. M., Purdie D. M., Dong W., Sargent D., Hedrick E., Kozloff M., Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). Journal of Clinical Oncology 2008 26 33 5326 5334 2-s2.0-56749169353 10.1200/JCO.2008.16.3212
43. Cohn A. L., Bekaii-Saab T., Bendell J. C., Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). Journal of Clinical Oncology 2010 28, article 15s. supplement; abstract 3596
44. Oncofacts.com [Website],. ASCO Gastrointestinal Cancer Symposium 2012, 2012
45. Machiels J. P., Sempoux C., Scalliet P., Coche J. C., Humblet Y., van Cutsem E., Kerger J., Canon J. L., Peeters M., Aydin S., Laurent S., Kartheuser A., Coster B., Roels S., Daisne J. F., Honhon B., Duck L., Kirkove C., Bonny M. A., Haustermans K., Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Annals of Oncology 2007 18 4 738 744 2-s2.0-34047179551 10.1093/annonc/mdl460 (Pubitemid 46523279)
46. Rodel C., Arnold D., Hipp M., Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. International Journal of Radiation Oncology Biology Physics 2008 70 1081 1086 (Pubitemid 351296110)
47. Crane C. H., Eng C., Feig B. W., Das P., Skibber J. M., Chang G. J., Wolff R. A., Krishnan S., Hamilton S., Janjan N. A., Maru D. M., Ellis L. M., Rodriguez-Bigas M. A., Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics 2010 76 3 824 830 2-s2.0-76049088643 10.1016/j.ijrobp.2009.02.037
48. Mourad J. J., des Guetz G., Debbabi H., Levy B. I., Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Annals of Oncology 2008 19 5 927 934 2-s2.0-43049085201 10.1093/annonc/mdm550 (Pubitemid 351627309)
49. Rougier R., Stroiakovski D., Kohne C., Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer (mCRC): updated survival data and influence of KRAS status on outcome in the CRYSTAL study. Proceedings of the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology 2009. abstract 443
50. van Cutsem E., Lang I., Folprecht G., Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. Journal of Clinical Oncology 2010 28, article 3570
51. Bokemeyer C., Bondarenko I., Hartmann J. T., de Braud F., Schuch G., Zubel A., Celik I., Schlichting M., Koralewski P., Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology 2011 22 7 1535 1546 2-s2.0-79956310674 10.1093/annonc/mdq632
52. Folprecht G., Gruenberger T., Hartmann J. T., Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). Proceedings of the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology January 2009 San Francisco, Calif, USA. abstract 296
53. Douillard J., Siena S., Cassidy J., Randomized phase III study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as first line treatment in patients with metastatic colorectal cancer (mCRC): the PRIME trial. European Journal of Cancer 2009 7, article 6
54. Peeters M., Price T., Hotko Y., Randomized phase III study (20050181) of panitumumab with FOLFIRI compared to FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer (mCRC). European Journal of Cancer 2009 7, article 9
55. Wolmark N., Yothers G., O'Connell M. J., A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. Journal of Clinical Oncology 2009 27, article 18s. supplement; abstract LBA4
56. Hoff P., Clarke S., Cunnigham D., A three-arm phase III randomized trial of FOLFOX-4 vs. FOLFOX-4 plus bevacizumab vs. XELOX plus bevacizumab in the adjuvant treatment of patients with stage III or high-risk stage II colon cancer: results of the interim safety analysis of the AVANT trial. European Journal of Cancer 2009 7, article 324
57. Alberts S. R., Sargent D. J., Smyrrk T. C., Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: results from NCCTG intergroup phase III trial NO147. Journal of Clinical Oncology 2010 28 18, supplement, article 959s. supplement; abstract CRA3507
58. Goldberg R. M., Sargent D. J., Thibodeau N., Adjuvant mFOLFOX6 plus or minus cetuximab in patients with KRAS mutant resected stage III colon cancer: NCCTG intergroup phase III trial NO147. Journal of Clinical Oncology 2010 28 15, supplement, article 262s
59. Gerard J. P., Azria D., Gourgou-Bourgade S., Conroy T., Bedenne L., Clinical results at 3 years of the ACCORD 12 randomized trial in rectal cancer. Journal of Clinical Oncology 2012 30 supplement 4. abstract 389
60. Aschele C., Pinto C., Cordio S., Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR) 01 randomized phase III trial. Journal of Clinical Oncology 2009 27 15, supplement. abstract CRA4008
61. Roh M. S., Yothers G. A., The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. Journal of Clinical Oncology 2011 29. abstract 3503
62. Gerard J. P., Conroy T., Bonnetain F., Preoperative radiotherapy with or without concurrent fl uorouracil and leucovorin in T3-T4 rectal cancers: results of FFCD 9203. Journal of Clinical Oncology 2006 24 4620 4625 (Pubitemid 46630960)
63. Bosset J. F., Collette L., Calais G., Mineur L., Maingon P., Radosevic-Jelic L., Daban A., Bardet E., Beny A., Ollier J. C., Chemotherapy with preoperative radiotherapy in rectal cancer. The New England Journal of Medicine 2006 355 11 1114 1123 2-s2.0-33748676449 10.1056/NEJMoa060829 (Pubitemid 44394918)
64. Bosset J. F., Calais G., Mineur L., Maingon P., Radosevic-Jelic L., Daban A., Bardet E., Beny A., Briffaux A., Collette L., Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary resultsEORTC 22921. Journal of Clinical Oncology 2005 23 24 5620 5627 2-s2.0-24944499364 10.1200/JCO.2005.02.113
65. Willett C. G., Boucher Y., di Tomaso E., Duda D. G., Munn L. L., Tong R. T., Chung D. C., Sahani D. V., Kalva S. P., Kozin S. V., Mino M., Cohen K. S., Scadden D. T., Hartford A. C., Fischman A. J., Clark J. W., Ryan D. P., Zhu A. X., Blaszkowsky L. S., Chen H. X., Shellito P. C., Lauwers G. Y., Jain R. K., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine 2004 10 2 145 147 2-s2.0-11144354392 10.1038/nm988 (Pubitemid 38524883)
66. Kuo T., Cho C. D., Halsey J., Wakelee H. A., Advani R. H., Ford J. M., Fisher G. A., Sikic B. I., Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. Journal of Clinical Oncology 2005 23 24 5613 5619 2-s2.0-24944484717 10.1200/JCO.2005.08.359
67. Bertolini F., Chiara S., Bengala C., Antognoni P., Dealis C., Zironi S., Malavasi N., Scolaro T., Depenni R., Jovic G., Sonaglio C., Rossi A., Luppi G., Conte P. F., Neoadjuvant treatment with single agent cetuximab followed by 5-FU, cetuximab and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics 2009 73 2 466 472 2-s2.0-58149345226 10.1016/j.ijrobp.2008.04.065
68. Velenik V., Ocvirk J., Oblak I., Anderluh F., Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer: results of a phase II trial. Journal of Clinical Oncology 2009 27. abstract e15029
69. Horisberger K., Treschl A., Mai S., MARGIT mannheimer arbeitsgruppe für gastrointestinale tumoren. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. International Journal of Radiation Oncology Biology Physics 2009 74 1487 1493
70. Chang G., Park I. J., You Y. N., Hu C., Hamilton S. R., Eng C., Neoadjuvant treatment response and outcomes in locally advanced rectal cancer: establishing oncologic benchmarks. Journal of Clinical Oncology 2011 29. supplement; abstract 3545
71. Rodel C., Martus P., Papadoupolos T., Fuzesi L., Klimpfinger M., Fietkau R., Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. Journal of Clinical Oncology 2005 23 8868 8696
72. Akimoto T., Hunter N. R., Buchmiller L., Mason K., Ang K. K., Milas L., Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clinical Cancer Research 1999 5 10 2884 2890 2-s2.0-0032719534 (Pubitemid 29493967)
73. Liang K., Ang K. K., Milas L., Hunter N., Fan Z., The epidermal growth factor receptor mediates radioresistance. International Journal of Radiation Oncology Biology Physics 2003 57 1 246 254 2-s2.0-0041563993 10.1016/S0360-3016(03)00511-X (Pubitemid 36959763)
74. Giralt J., de las Heras M., Cerezo L., Eraso A., Hermosilla E., Velez D., Lujan J., Espin E., Rossello J., Majó J., Benavente S., Armengol M., de Torres I., The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiotherapy and Oncology 2005 74 2 101 108 2-s2.0-20044383380 10.1016/j.radonc.2004.12.021 (Pubitemid 40331866)
75. Kim J. S., Kim J. M., Li S., Yoon W. H., Song K. S., Kim K. H., Yeo S. G., Nam J. S., Cho M. J., Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. International Journal of Radiation Oncology Biology Physics 2006 66 1 195 200 2-s2.0-33746824624 10.1016/j.ijrobp.2006.04. 026 (Pubitemid 44175651)
76. Hartley A., Ho K. F., McConkey C., Geh J. I., Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. British Journal of Radiology 2005 78 934 934 938 2-s2.0-27744566164 10.1259/bjr/86650067 (Pubitemid 41582245)
77. Bonner J. A., Harari P. M., Giralt J., Azarnia N., Shin D. M., Cohen R. B., Jones C. U., Sur R., Raben D., Jassem J., Ove R., Kies M. S., Baselga J., Youssoufian H., Amellal N., Rowinsky E. K., Ang K. K., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine 2006 354 6 567 578 2-s2.0-32144433159 10.1056/NEJMoa053422 (Pubitemid 43209104)
78. Baumann M., Krause M., Dikomey E., Dittmann K., Dörr W., Kasten-Pisula U., Rodemann H. P., EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiotherapy and Oncology 2007 83 3 238 248 2-s2.0-34250345258 10.1016/j.radonc.2007.04.006 (Pubitemid 46915540)
79. Eriksen J. G., Steiniche T., Overgaard J., Danish Head and Neck Cancer Study Group (DAHANCA), The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiotherapy and Oncology 2005 74 93 100 (Pubitemid 40331865)
80. Chung K. Y., Minsky B., Schrag D., Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. Journal of Clinical Oncology 2006 24 18, supplement. abstract 3560
81. Maughan T., Adams R. A., Smith C. G., Addition of cetuximab to oxaliplatin based combination chemotherapy in patients with Kras wild-type advanced colorectal cancer (ACRC); a randomised superiority trial (MRC COIN). European Journal of Cancer 2009 7, supplement, article 4. abstract 6LBA
82. Morelli M. P., Cascone T., Troiani T., de Vita F., Orditura M., Laus G., Eckhardt S. G., Pepe S., Tortora G., Ciardiello F., Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Annals of Oncology 2005 16 4 iv61 iv68 2-s2.0-30444445564 10.1093/annonc/mdi910 (Pubitemid 43084948)
83. Bengala C., Bettelli S., Bertolini F., Salvi S., Chiara S., Sonaglio C., Losi L., Bigiani N., Sartori G., Dealis C., Malavasi N., D'Amico R., Luppi G., Gatteschi B., Maiorana A., Conte P. F., Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Annals of Oncology 2009 20 3 469 474 2-s2.0-61649088414 10.1093/annonc/mdn647
84. Pinto C., di Fabio F., Maiello E., Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Annals of Oncology 2011 22 11 2424 2430
85. Fisher G. A., Kuo T., Ramsey M., Schwartz E., Rouse R. V., Cho C. D., Halsey J., Sikic B. I., A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clinical Cancer Research 2008 14 21 7074 7079 2-s2.0-58149242890 10.1158/1078-0432.CCR-08-1014
86. Das P., Eng C., Rodriguez-Bigas M. A., Phase I trial of preoperative radiation therapy with concurrent capecitabine, bevacizumab and erlotinib for rectal adenocarcinoma. Proceedings of the ASTRO Annual Meeting 2011. abstract 193
87. Blaszkowsky L. S., Hong T. S., Zhu A. X., A phase I/II study of bevacizumab, erlotinib, and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Journal of Clinical Oncology 2009 27 15, supplement, article 194S. abstract 4106
88. Peeters K. C. M. J., Marijnen C. A. M., Nagtegaal I. D., Kranenbarg E. K., Putter H., Wiggers T., Rutten H., Pahlman L., Glimelius B., Leer J. W., van de Velde C. J. H., The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Annals of Surgery 2007 246 5 693 701 2-s2.0-34548557656 10.1097/01.sla.0000257358.56863.ce (Pubitemid 350035641)
89. Visser O., Bakx R., Zoetmulder F. A. N., Levering C. C., Meijer S., Slors J. F. M., Van Lanschot J. J. B., The influence of total mesorectal excision on local recurrence and survival in rectal cancer patients: a population-based study in greater Amsterdam. Journal of Surgical Oncology 2007 95 6 447 454 2-s2.0-34248149562 10.1002/jso.20713 (Pubitemid 46709387)
90. Aschele C., Pinto C., Cordio S., Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. Journal of Clinical Oncology 2009 27 supplement 18, article 4008
91. Gerard J. P., Azria D., Gourgou-Bourgade S., Martel-Laffay I., Hennequin C., Etienne P. L., Vendrely V., Franois E., de la Roche G., Bouché O., Mirabel X., Denis B., Mineur L., Berdah J. F., Mahé M. A., Bécouarn Y., Dupuis O., Lledo G., Montoto-Grillot C., Conroy T., Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial accord 12/0405-Prodige 2. Journal of Clinical Oncology 2010 28 10 1638 1644 2-s2.0-77950495945 10.1200/JCO.2009.25.8376
92. Whithers H. R., Taylor J. M. G., Maciejewski B., The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncologica 1988 27 2 131 146 2-s2.0-0023894783
93. Taghian A. G., Abi-Raad R., Asaad S. I., Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancer cancers in patients treated with neoadjuvant chemotherapy: clinical implications. Journal of Clinical Oncology 2005 23 1951 1961 (Pubitemid 46211374)
94. Marquardt F., Rodel F., Capalbo G., Molecular targeted treatment and radiation therapy for rectal cancer. Strahlentherapie Und Onkologie 2009 185 371 378
95. Rödel C., Sauer R., Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlentherapie und Onkologie 2007 183 5 227 235 2-s2.0-34248200382 10.1007/s00066-007-9000-9 (Pubitemid 46725993)
96. Chua Y. J., Barbachano Y., Cunningham D., Oates J. R., Brown G., Wotherspoon A., Tait D., Massey A., Tebbutt N. C., Chau I., Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. The Lancet Oncology 2010 11 3 241 248 2-s2.0-77349110719 10.1016/S1470-2045(09)70381-X
97. Chau I., Brown G., Cunningham D., Tait D., Wotherspoon A., Norman A. R., Tebbutt N., Hill M., Ross P. J., Massey A., Oates J., Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. Journal of Clinical Oncology 2006 24 4 668 674 2-s2.0-33644846344 10.1200/JCO.2005.04. 4875 (Pubitemid 46630432)
98. Fernández-Martos C., Pericay C., Aparicio J., Salud A., Safont M., Massuti B., Vera R., Escudero P., Maurel J., Marcuello E., Mengual J. L., Saigi E., Estevan R., Mira M., Polo S., Hernandez A., Gallen M., Arias F., Serra J., Alonso V., Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 study. Journal of Clinical Oncology 2010 28 5 859 865 2-s2.0-77649209505 10.1200/JCO.2009.25.8541
99. Saif M. W., Elfiky A., Salem R. R., Gastrointestinal perforation due to bevacizumab in colorectal cancer. Annals of Surgical Oncology 2007 14 6 1860 1869 2-s2.0-34249894171 10.1245/s10434-006-9337-9 (Pubitemid 46870935)
100. Nogué M., Salud A., Vicente P., Arriví A., Roca J. M., Losa F., Ponce J., Safont M. J., Guasch I., Moreno I., Ruiz A., Pericay C., Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 2011 16 5 614 620 2-s2.0-79956268951 10.1634/theoncologist.2010-0285
101. Dewdney A., Cunningham D., Tabernero J., Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). Journal of Clinical Oncology 2012 30 14 1620 1627
102. Chu Q. S. C., Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opinion on Biological Therapy 2009 9 2 263 271 2-s2.0-65349186800 10.1517/14712590802666397
103. Clinicaltrials.gov [Website], Aflibercept versus placebo in combination with irinotecan and 5-FU in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin based regimen (VELOUR). 2010
104. Spratlin J. L., Cohen R. B., Eadens M., Gore L., Camidge D. R., Diab S., Leong S., O'Bryant C., Chow L. Q. M., Serkova N. J., Meropol N. J., Lewis N. L., Chiorean E. G., Fox F., Youssoufian H., Rowinsky E. K., Eckhardt S. G., Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. Journal of Clinical Oncology 2010 28 5 780 787 2-s2.0-77649213706 10.1200/JCO.2009.23.7537
105. Spratlin J. L., Mulder K. E., MacKey J. R., Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncology 2010 6 7 1085 1094 2-s2.0-77954682879 10.2217/fon.10.75
106. Clinicaltrials.gov [Website], A study in second line metastatic colorectal cancer. 2012
107. Kies M. S., Blumenschein G. R. Jr., Christensen O., Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2010 28 15, supplement. abstract 7585
108. Grothey A., Sobrero A., Siena S., Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. Journal of Clinical Oncology 2012 30 supplement 4. abstract LBA385
109. Gills J. J., Dennis P. A., Perifosine: update on a novel Akt inhibitor. Current Oncology Reports 2009 11 2 102 110 2-s2.0-60349088457 10.1007/s11912-009-0016-4
110. Carnero A., The PKB/AKT pathway in cancer. Current Pharmaceutical Design 2010 16 1 34 44 2-s2.0-77949452524 10.2174/138161210789941865
111. Clinicaltrials.gov [Website], Perifosine plus capecitabine versus placebo plus capecitabine in patients with refractory advanced colorectal cancer. 2010
112. Becher O. J., Hambardzumyan D., Walker T. R., Helmy K., Nazarian J., Albrecht S., Hiner R. L., Gall S., Huse J. T., Jabado N., MacDonald T. J., Holland E. C., Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Research 2010 70 6 2548 2557 2-s2.0-77950232139 10.1158/0008-5472.CAN-09-2503
113. Gao Y., Ishiyama H., Sun M., Brinkman K. L., Wang X., Zhu J., Mai W., Huang Y., Floryk D., Ittmann M., Thompson T. C., Butler E. B., Xu B., Teh B. S., The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiation Oncology 2011 6 1, article 38 2-s2.0-79955076869 10.1186/1748-717X-6-38
114. Cai Z. W., Zhang Y., Borzilleri R. M., Qian L., Barbosa S., Wei D., Zheng X., Wu L., Fan J., Shi Z., Wautlet B. S., Mortillo S., Jeyaseelan R., Kukral D. W., Kamath A., Marathe P., D'Arienzo C., Derbin G., Barrish J. C., Robl J. A., Hunt J. T., Lombardo L. J., Fargnoli J., Bhide R. S., Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol- 5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl) 2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). Journal of Medicinal Chemistry 2008 51 6 1976 1980 2-s2.0-41149122199 10.1021/jm7013309 (Pubitemid 351438880)
115. Huynh H., Ngo V. C., Fargnoli J., Ayers M., Khee C. S., Heng N. K., Choon H. T., Hock S. O., Chung A., Chow P., Pollock P., Byron S., Tran E., Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clinical Cancer Research 2008 14 19 6146 6153 2-s2.0-58149175849 10.1158/1078-0432.CCR-08-0509
116. Siu L., Shapiro J., Jonker D., Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): the NCIC Clinical Trials Group and AGITG CO.20 trial. Journal of Clinical Oncology 2012 30 supplement 4. abstract 386
117. Clinicaltrials.gov [Website], Irinotecan plus brivanib in metastatic colorectal cancer (CRC) enriched for elevated levels of plasma FGF. 2012
118. Shen B. Q., Lee D. Y., Zioncheck T. F., Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. The Journal of Biological Chemistry 1999 274 46 33057 33063 2-s2.0-0032730327 10.1074/jbc.274.46.33057 (Pubitemid 129535347)
119. Kabbinavar F. F., Hambleton J., Mass R. D., Hurwitz H. I., Bergsland E., Sarkar S., Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. Journal of Clinical Oncology 2005 23 16 3706 3712 2-s2.0-20544471876 10.1200/JCO.2005.00.232
120. Flynn P. J., Sugrue M. M., Purdie D. M., Serious bleeding events are uncommon in patients (pts) with netastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a fi rst-line regimen: results from the BRiTE Observational Cohort Study. Proceedings of the Gastrointestinal Cancers Symposium 2008. abstract 346
121. Ferrara N., Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney International 1999 56 3 794 814 2-s2.0-0032881898 10.1046/j.1523-1755.1999.00610.x (Pubitemid 29411709)
122. Allegra C. J., Yothers G., O'Connell M. J., Sharif S., Colangelo L. H., Lopa S. H., Petrelli N. J., Goldberg R. M., Atkins J. N., Seay T. E., Fehrenbacher L., O'Reilly S., Chu L., Azar C. A., Wolmark N., Initial safety report of NSABP C- 08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. Journal of Clinical Oncology 2009 27 20 3385 3390 2-s2.0-66149147757 10.1200/JCO.2009.21.9220
123. Sugrue M., Kozloff M., Hainsworth J., Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. Journal of Clinical Oncology 2006 24 18, supplement, article 3535
124. Hapani S., Chu D., Wu S., Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. The Lancet Oncology 2009 10 6 559 568 2-s2.0-66149121478 10.1016/S1470-2045(09)70112-3
125. Genentech, Avastin (bevacizumab) prescribing information. 2006
126. Saltz L., Kies M., Abbruzzese J. L., The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. American Society of Clinical Oncology Proceedings 2003 22, article 817
127. van Cutsem E., Humblet Y., Gelderblom H., Cetuximab dose-escalation study in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. Proceedings of the Gastrointestinal Cancers Symposium 2007. abstract 237
128. Schrag D., Chung K. Y., Flombaum C., Saltz L., Cetuximab therapy and symptomatic hypomagnesemia. Journal of the National Cancer Institute 2005 97 16 1221 1224 2-s2.0-23844555670 10.1093/jnci/dji242 (Pubitemid 41258228)
129. Perrin C., Fabre C., Raoul J. L., Boucher E., Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment. Acta Oncologica 2006 45 8 1135 1136 2-s2.0-33751345061 10.1080/02841860600871095 (Pubitemid 44808503)
130. Wolf F. I., Trapani V., Cittadini A., Maier J. A. M., Hypomagnesaemia in oncologic patients: to treat or not to treat? Magnesium Research 2009 22 1 5 9 2-s2.0-66149105860 10.1684/mrh.2009.0157
131. Chung C. H., Mirakhur B., Chan E., Le Q. T., Berlin J., Morse M., Murphy B. A., Satinover S. M., Hosen J., Mauro D., Slebos R. J., Zhou Q., Gold D., Hatley T., Hicklin D. J., Platts-Mills T. A. E., Cetuximab-induced anaphylaxis and IgE specific for galactose- α -1,3- galactose. The New England Journal of Medicine 2008 358 11 1109 1117 2-s2.0-40849142102 10.1056/NEJMoa074943 (Pubitemid 351398485)
132. Tappenden P., Jones R., Paisley S., Carroll C., The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. European Journal of Cancer 2007 43 17 2487 2494 2-s2.0-36048939391 10.1016/j.ejca.2007.08.017 (Pubitemid 350086932)
133. Jansman F. G. A., Postma M. J., Brouwers J. R. B. J., Cost considerations in the treatment of colorectal cancer. PharmacoEconomics 2007 25 7 537 562 2-s2.0-34447263280 10.2165/00019053-200725070-00002 (Pubitemid 47048039)
134. Starling N., Tilden D., White J., Cunningham D., Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. British Journal of Cancer 2007 96 2 206 212 2-s2.0-33846477195 10.1038/sj.bjc.6603561 (Pubitemid 46160622)
135. Annemans L., van Cutsem E., Humblet Y., van Laethem J. L., Bleiberg H., Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecana Belgian analysis. Acta Clinica Belgica 2007 62 6 419 425 2-s2.0-39049148881 (Pubitemid 351236175)
136. Schrag D., The price tag on progresschemotherapy for colorectal cancer. The New England Journal of Medicine 2004 351 4 317 319 2-s2.0-3242686833 10.1056/NEJMp048143 (Pubitemid 38944397)
137. Tappenden P., Jones R., Paisley S., Carroll C., Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technology Assessment 2007 11 12 1 128 2-s2.0-34547699641
138. Meropol N. J., Schrag D., Smith T. J., Mulvey T. M., Langdon R. M., Blum D., Ubel P. A., Schnipper L. E., American Society of Clinical Oncology guidance statement: the cost of cancer care. Journal of Clinical Oncology 2009 27 23 3868 3874 2-s2.0-68949112230 10.1200/JCO.2009.23.1183